Investigational · not FDA approved

Editorially reviewed · Last updated February 2026 · How we review

Cagrilintide and Tirzepatide: Stacking Amylin With a Dual Agonist — What the Data Actually Says

Q: Can you take cagrilintide and tirzepatide together?

No clinical trial has studied this combination in humans. The only published data is a 12-day preclinical study in rats (ADA 2024) showing synergistic weight loss at submaximal doses. Eli Lilly is currently conducting a Phase 2 trial (NCT06603571) of its own amylin agonist (eloralintide) combined with tirzepatide, but results are not yet available. This combination should only be considered under direct physician supervision.

Q: What is the cagrilintide dosage with tirzepatide?

No established dosing protocol exists because this combination has not been studied in clinical trials. Tirzepatide follows its standard FDA-approved titration (2.5 mg to 15 mg once weekly). Cagrilintide has been studied at doses from 0.3 mg to 4.5 mg once weekly in the CagriSema program. Any combination dosing would need to be determined by a physician.

Q: Is cagrilintide the same as CagriSema?

No. Cagrilintide is one of the two components of CagriSema. CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide (2.4 mg, an amylin analog) and semaglutide (2.4 mg, a GLP-1 agonist) in a single once-weekly injection. Cagrilintide alone is not FDA-approved for any indication.

Q: Did CagriSema beat tirzepatide in the head-to-head trial?

No. In REDEFINE 4 (results announced February 23, 2026), CagriSema achieved 23.0% weight loss versus tirzepatide's 25.5% at 84 weeks. CagriSema failed to demonstrate non-inferiority to tirzepatide. Novo Nordisk is developing a higher-dose version (REDEFINE 11) expected in 2027.

Q: Is retatrutide better than cagrilintide plus tirzepatide?

No direct comparison exists. Retatrutide achieved 28.7% weight loss at 68 weeks in TRIUMPH-4 using a single molecule targeting three receptors (GLP-1, GIP, glucagon). Cagrilintide + tirzepatide has never been studied together in humans. Retatrutide offers a simpler approach (one injection, one clinically-studied drug) but uses a different mechanism (glucagon instead of amylin). For a detailed comparison, see Retatrutide vs CagriSema.

Q: What is eloralintide?

Eloralintide is Eli Lilly's investigational amylin receptor agonist (previously LY3841136). In Phase 2, it achieved up to 20.1% weight loss as monotherapy at 48 weeks. Lilly is currently studying it in combination with tirzepatide in a Phase 2 trial (NCT06603571) for adults with obesity and type 2 diabetes. Phase 3 monotherapy enrollment began in late 2025.

Searches for "cagrilintide dosage with tirzepatide" have surged as people look for ways to break through weight loss plateaus on tirzepatide (Mounjaro/Zepbound). The idea is straightforward: add cagrilintide, an amylin analog that works through entirely different receptors, to get additional appetite suppression that tirzepatide alone cannot provide.

This page covers what the published science actually says about combining these two drugs, the preclinical and clinical evidence, the safety concerns, and where retatrutide fits as a potentially simpler alternative.

What Each Drug Does

	Tirzepatide (Mounjaro/Zepbound)	Cagrilintide
Drug class	Dual incretin agonist	Long-acting amylin analog
Receptors	GLP-1 + GIP	Amylin (AMY1R, AMY3R) + Calcitonin
Manufacturer	Eli Lilly	Novo Nordisk
FDA status	Approved (Mounjaro 2022, Zepbound 2023)	Not approved (NDA filed as part of CagriSema, Dec 2025)
Dosing	Once weekly injection, 2.5-15 mg	Once weekly injection (studied at 0.3-4.5 mg in trials)
Max weight loss	-22.5% (SURMOUNT-1, 72 weeks)	-11.8% monotherapy (REDEFINE 1, 68 weeks)
Primary side effects	Nausea, diarrhea, constipation	Nausea, fatigue, injection site reactions

The key point: these drugs target completely non-overlapping receptor systems. Tirzepatide works through incretin signaling (GLP-1 + GIP). Cagrilintide works through amylin signaling in the brainstem. This is why the combination concept exists — two independent appetite suppression pathways stacked together.

Why People Are Combining Them

The core motivation is appetite suppression plateau on tirzepatide.

A December 2025 case study published in Nature Medicine documented this phenomenon directly. Penn Medicine researchers implanted intracranial electrodes in a patient on tirzepatide and observed that reward-center (nucleus accumbens) activity went silent initially — the patient reported no food preoccupation. After five months at full dose, brain reward-center activity returned along with severe food cravings. The appetite-suppressing effect of tirzepatide had worn off while the patient was still on the drug.

Cagrilintide targets a completely different neural pathway (amylin receptors in the area postrema and brainstem satiety centers). The hypothesis is that adding amylin agonism can restore appetite suppression through a pathway that has not developed tolerance.

This is the same rationale behind Novo Nordisk's CagriSema: they combined cagrilintide with semaglutide (a GLP-1 agonist) and demonstrated that the combination produced 22.7% weight loss versus 16.1% for semaglutide alone in REDEFINE 1 — showing that amylin agonism meaningfully adds to incretin-based weight loss.

People stacking cagrilintide with tirzepatide are essentially trying to apply the CagriSema principle to a stronger base drug (tirzepatide instead of semaglutide).

Published Evidence for the Combination

Preclinical Data: ADA 2024

The only published data on the specific cagrilintide + tirzepatide combination comes from a preclinical study presented as a poster at the American Diabetes Association 2024 Scientific Sessions:

Treatment	Weight Loss (12 days)	Notes
Cagrilintide 3 nmol/kg	-7.2%	Amylin agonist alone
Cagrilintide 10 nmol/kg	-9.6%	Higher dose
Tirzepatide 3 nmol/kg	-2.5%	Dual incretin alone
Tirzepatide 10 nmol/kg	-5.8%	Higher dose
Combination (3 + 3 nmol/kg)	-11.0%	Submaximal doses, synergistic effect (P<0.05)

The combination at submaximal doses produced greater weight loss than either drug alone at maximal doses. It also showed superior ALT reduction and lower plasma triglycerides. The authors concluded this suggests a "potential opportunity for further clinical development."

However, this was a 12-day study in diet-induced obese rats — not humans.

CagriSema vs Tirzepatide: REDEFINE 4 (February 2026)

The closest human evidence comes from REDEFINE 4, Novo Nordisk's head-to-head trial comparing CagriSema (cagrilintide + semaglutide) against tirzepatide:

	CagriSema 2.4/2.4 mg	Tirzepatide 15 mg
Weight loss (adherent)	-23.0%	-25.5%
Weight loss (all enrolled)	-20.2%	-23.6%
Primary endpoint	FAILED — did not demonstrate non-inferiority	Won
Duration	84 weeks	84 weeks
Participants	809 total

CagriSema failed to match tirzepatide on weight loss. This is significant for the stacking question: if Novo Nordisk's optimized combination of amylin + GLP-1 could not beat tirzepatide's dual GLP-1/GIP mechanism, it raises questions about whether adding cagrilintide to tirzepatide would produce meaningfully better results than tirzepatide alone at an optimized dose.

Eli Lilly's Answer: Eloralintide + Tirzepatide

Eli Lilly is developing its own amylin agonist, eloralintide, and is actively studying it in combination with tirzepatide in a Phase 2 trial (NCT06603571). This trial has nine treatment arms plus placebo, enrolling adults with obesity and type 2 diabetes, with a primary endpoint of weight change at 48 weeks.

Eloralintide monotherapy showed strong results in Phase 2:

Dose	Weight Loss (48 weeks)
Eloralintide 1 mg	-9.5%
Eloralintide 3 mg	-12.4%
Eloralintide 6 mg	-17.6%
Eloralintide 9 mg	-20.1%
Placebo	-0.4%

Lilly has stated it is "evaluating [eloralintide's] use as a complementary treatment to incretin therapy" — the pharmaceutical industry's version of amylin + incretin stacking. Results from the combination trial are not yet available.

Safety Concerns

No formal safety data exists for the cagrilintide + tirzepatide combination. The following concerns are inferred from each drug's individual safety profile:

Additive gastroparesis risk — Both cagrilintide (via amylin) and tirzepatide (via GLP-1) slow gastric emptying through different mechanisms. Combining them could cause severe gastroparesis. No clinical data quantifies this risk.

Excessive appetite suppression — Amylin agonism is a potent appetite suppressant. Combined with tirzepatide's dual mechanism, caloric intake could drop to levels that promote muscle loss, metabolic adaptation, and nutritional deficiencies.

Fatigue — Fatigue is the most consistently reported side effect from cagrilintide. This matches known amylin receptor biology — amylin agonism can affect energy levels through brainstem pathways.

No long-term safety data — Neither cagrilintide (as a standalone) nor eloralintide has multi-year safety data. The combination has zero human safety data.

Drug interaction unknowns — Tirzepatide and cagrilintide have never been studied together in a controlled setting. Pharmacokinetic interactions, if any, are unknown.

Where Retatrutide Fits

People stacking cagrilintide with tirzepatide are trying to achieve multi-pathway weight loss by combining two separate injections from two different companies. Retatrutide takes a fundamentally different approach: one molecule, three receptors.

	Cagrilintide + Tirzepatide (stacked)	Retatrutide
Pathways	4 (GLP-1 + GIP + Amylin + Calcitonin)	3 (GLP-1 + GIP + Glucagon)
Injections	2 separate injections per week	1 injection per week
Clinical data	Zero human combination trials	Phase 3 (TRIUMPH program, 5,800+ participants)
Max weight loss	Unknown (no human data)	-28.7% at 68 weeks (TRIUMPH-4)
Unique mechanism	Amylin (appetite via brainstem)	Glucagon (increases energy expenditure)
FDA status	Neither approved as combination	Phase 3, approval expected 2027

Retatrutide does not hit the amylin pathway — it uses glucagon agonism instead, which increases energy expenditure and promotes fat oxidation. This is a different strategy: rather than adding a second appetite suppression pathway (amylin), retatrutide attacks the other side of the energy equation by increasing how many calories the body burns.

The result — 28.7% weight loss from a single, clinically-studied molecule — exceeds what CagriSema achieved (23.0%) against tirzepatide in the REDEFINE 4 head-to-head trial. It also does so without the complexity of managing two separate drugs, unknown interactions, and pH-sensitive reconstitution.

For a full comparison, see Retatrutide vs CagriSema.

Frequently Asked Questions

Can you take cagrilintide and tirzepatide together?

No clinical trial has studied this combination in humans. The only published data is a 12-day preclinical study in rats (ADA 2024) showing synergistic weight loss at submaximal doses. Eli Lilly is currently conducting a Phase 2 trial (NCT06603571) of its own amylin agonist (eloralintide) combined with tirzepatide, but results are not yet available. This combination should only be considered under direct physician supervision.

What is the cagrilintide dosage with tirzepatide?

No established dosing protocol exists because this combination has not been studied in clinical trials. Tirzepatide follows its standard FDA-approved titration (2.5 mg to 15 mg once weekly). Cagrilintide has been studied at doses from 0.3 mg to 4.5 mg once weekly in the CagriSema program. Any combination dosing would need to be determined by a physician.

Is cagrilintide the same as CagriSema?

No. Cagrilintide is one of the two components of CagriSema. CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide (2.4 mg, an amylin analog) and semaglutide (2.4 mg, a GLP-1 agonist) in a single once-weekly injection. Cagrilintide alone is not FDA-approved for any indication.

Did CagriSema beat tirzepatide in the head-to-head trial?

No. In REDEFINE 4 (results announced February 23, 2026), CagriSema achieved 23.0% weight loss versus tirzepatide's 25.5% at 84 weeks. CagriSema failed to demonstrate non-inferiority to tirzepatide. Novo Nordisk is developing a higher-dose version (REDEFINE 11) expected in 2027.

Is retatrutide better than cagrilintide plus tirzepatide?

No direct comparison exists. Retatrutide achieved 28.7% weight loss at 68 weeks in TRIUMPH-4 using a single molecule targeting three receptors (GLP-1, GIP, glucagon). Cagrilintide + tirzepatide has never been studied together in humans. Retatrutide offers a simpler approach (one injection, one clinically-studied drug) but uses a different mechanism (glucagon instead of amylin). For a detailed comparison, see Retatrutide vs CagriSema.

What is eloralintide?

Eloralintide is Eli Lilly's investigational amylin receptor agonist (previously LY3841136). In Phase 2, it achieved up to 20.1% weight loss as monotherapy at 48 weeks. Lilly is currently studying it in combination with tirzepatide in a Phase 2 trial (NCT06603571) for adults with obesity and type 2 diabetes. Phase 3 monotherapy enrollment began in late 2025.

Sources

Valdecantos, M.P., Rada, P., et al. (2024). Beneficial Effect of the Combination Therapy of Cagrilintide and Tirzepatide on Body Weight Loss in Obese Rats. Diabetes, 73(Supplement_1), 300-OR. DOI: 10.2337/db24-300-OR
Aronne, L.J., et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2502081
Novo Nordisk. (2026). CagriSema demonstrated 23% weight loss in open-label head-to-head REDEFINE 4 trial. Press release
Eli Lilly. (2025). Eloralintide Phase 2 results. Press release
ClinicalTrials.gov. Eloralintide + Tirzepatide Phase 2. NCT06603571
Eli Lilly. (2025). TRIUMPH-4 results. Press release
Shaker, A., et al. (2025). Intracranial recording of reward circuitry in a patient receiving tirzepatide. Nature Medicine. DOI: 10.1038/s41591-025-04035-5

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources